Nyrada, Inc. · ASX:NYR
Nyrada — Investor Presentation (September 2026)
33 slides from Nyrada's investor presentation, Sep 21, 2026
Slide 1: Capital Raising Presentation: Building the Future of TRPC-based Therapies
rsonal use only Capital Raising Presentation Building the Future of TRPC-based Therapies 21 September 2026 ASX:NYR Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board Not for release to US wire services or distribution in the United States
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not be considered as an offer or invitation to subscribe for, or purchase any securities in NYR, or as an inducement to purchase any securities in NYR. No agreement to subscribe for secu
Slide 3: Investment Highlights
Investment Highlights Advancing first-in-class TRPC inhibitor with multiple near-term value catalysts rsonal use only Platform asset with Positive Phase I safety Near term Phase IIa High unmet need Strong IP & Uniquely Multiple near-term data supporting and pharmacokinetic safety and efficacy opport
Slide 4: Nyrada and the Xolatryp Program
Nyrada and the Xolatryp® Program Nyrada is a world leading developer of TRPC-targeted therapies, providing exposure to an emerging and increasingly recognised therapeutic frontier rsonal use only › Nyrada Inc (ASX:NYR) is a clinical-stage biotechnology company developing a first-in-class small molec
Slide 5: Management
Management Experienced leadership across drug development and commercialisation Leadership Team rsonal use only Jasneet James Bonnar Benny Evison Alex Parmar Dimitri Burshtein Managing Ph.D Suchowerska Director of Investor Director & CEO Chief Scientific Ph.D Ph.D Relations and Officer Director of C
Slide 6: Board of Directors
Board of Directors Experienced leadership across drug development and commercialisation Board Members rsonal use only John Moore Christopher Marcus Dr Rüdiger Dr Ian Dixon James Bonnar Non-Executive Cox Frampton Weseloh Non-Executive Managing Director Chairman Non-Executive Non-Executive Director &
Slide 7: TRPC Channels: Clinical Landscape & Validation
TRPC Channels: Clinical Landscape & Validation Growing industry investment supports the emergence of TRPC therapeutics • Genetic validation and strong preclinical data have led to advancing clinical programs First TRPC Program to Reach Phase III rsonal use only across cardiovascular, kidney, neurolo
Slide 8: Xolatryp Mechanism of Action
Xolatryp® Mechanism of Action Nyrada’s lead candidate Xolatryp® is a novel gatekeeper of calcium influx with broad therapeutic potential Overview Cardioprotection rsonal use only • Xolatryp® is a third generation TRPC 3/6/7 channel inhibitor TRPC3 TRPC6 TRPC7 • Highly differentiated, proven target w
Slide 9: Xolatryp as a Platform Therapy
Xolatryp® as a Platform Therapy Highly focused multi-indication therapy addressing high unmet need in well-defined markets Xolatryp® rsonal use only 1 Candidate 3 Current Cardioprotection Oncology Neuroprotection Applications (secondary brain injury) Cardiac Reperfusion Injury Adjunct in Anthracycli
Slide 10: Diversified Pipeline
Diversified Pipeline Multiple compelling TRPC opportunities in indications of high unmet need rsonal use only Target Strategy and Upcoming Applications Pre-clinical Phase I Phase II Phase III Indication Catalysts • Safety review in H2 CY26 Cardiac Phase IIa • Topline data in Q3/Q4 CY27, Cardioprotec
Slide 11: Xolatryp Phase I Clinical Trial
Xolatryp® Phase I Clinical Trial Primary endpoint met with all doses safe and well-tolerated, with no dose-limiting, or dose-related safety issues Trial Overview rsonal use only Xolatryp Levels in Cohort 6 • Double-blinded, randomised, placebo-controlled Phase I study in 48 healthy volunteers 10 • 3
Slide 12: Xolatryp in Cardiac Reperfusion Injury
rsonal use only Xolatryp® in Cardiac Reperfusion Injury Well defined and uncontested $US3bn market opportunity
Slide 13: Heart Attack (STEMI)
Heart Attack (STEMI) STEMI results in a hyper-activation of TRPC channels Overview STEMI rsonal use only • Atherosclerotic plaque restricts blood flow to a region of the heart muscle resulting in Myocardial Infarction (MI) “Heart attack” • STEMI (ST-elevation myocardial infarction) is a blockage • M
Slide 14: Current Standard Treatment for STEMI Heart Attack
Current Standard Treatment for STEMI Heart Attack Up to ~50% of heart injury may be caused by reperfusion, representing a major remaining therapeutic challenge rsonal use only Infarct size as a driver of heart failure Current Standard of Care for The Clinical Paradox from PCI risk and mortality STEM
Slide 15: STEMI Heart Attack – Large Uncontested Market Opportunity
STEMI Heart Attack – Large Uncontested Market Opportunity US$3bn STEMI opportunity rsonal use only US Market Opportunity ~750K >80% ~600K US$5,000 US$3bn = STEMI¹ STEMI related PCI¹ Illustrative price² ✕ ✕ Total addressable Estimated PCI market in the US Annual STEMI Illustrative price procedures re
Slide 16: Xolatryp Cardioprotective Function
Xolatryp® Cardioprotective Function Strong, consistent Cardioprotection across models of myocardial infarction Two preclinical studies evaluated Xolatryp® in myocardial ischemia-reperfusion (I/R) injury models. One assessed early arrhythmia events and biomarkers over 3 hours, the rsonal use only oth
Slide 17: PROTECT-MI: Phase IIa Trial Design
PROTECT-MI: Phase IIa Trial Design Phase IIa Cardiac Reperfusion Injury clinical trial currently recruiting PROTECT-MI is a Phase IIa randomised, double-blind, placebo-controlled study 100 evaluable patients (placebo and drug rsonal use only evaluating Xolatryp® in STEMI patients undergoing PCI Size
Slide 18: Other Indications across Oncology & Neuroprotection
rsonal use only Other Indications across Oncology & Neuroprotection
Slide 19: Oncology – Antiproliferative
Oncology – Antiproliferative Xolatryp® enhances anthracycline anti-tumour efficacy as a novel adjunct oncology therapy Xolatryp® Enhances Standard Chemotherapy Efficacy and Safety rsonal use only ANTI-PROLIFERATIVE • Novel TRPC3/6/7 inhibitor targeting calcium-dependent tumour growth pathways Cancer
Slide 20: Oncology – Cardioprotective
Oncology – Cardioprotective Xolatryp® demonstrates cardioprotection during anthracycline treatment Xolatryp® Enhances Standard Chemotherapy Efficacy and Safety rsonal use only CARDIOPROTECTION • Novel TRPC3/6/7 inhibitor targeting calcium dysregulation implicated in anthracycline-induced Doxorubicin
Slide 21: Neuroprotection
Neuroprotection Xolatryp® targets secondary injury following Ischemic Stroke and Traumatic Brain Injury Overview rsonal use only • Ischemic stroke and traumatic brain injury (TBI) trigger secondary injury pathways that drive ongoing neuronal damage • Excess intracellular Ca²⁺ is a key mediator of ex
Slide 22: Catalysts
Catalysts Multiple near-term milestones over the next 18 months 2H CY26 1H CY27 2H CY27 rsonal use only • PROTECT-MI Phase IIa execution: ongoing patient • PROTECT-MI Phase IIa execution: ongoing patient • Phase IIa PROTECT-MI topline data readout recruitment and site activations across Australian r
Slide 23: Offer Details
rsonal use only Offer Details
Slide 24: Capital Raising Overview
Capital Raising Overview The Company is raising approximately A$14 million via a Placement & SPP • An institutional Placement of new CHESS Depositary Interests (“New CDIs”) in the Company to sophisticated and professional investors (“Placement”) to raise A$12.0 million (before costs) rsonal use only
Slide 25: Sources and Use of Funds
Sources and Use of Funds The proceeds will fully fund the PROTECT-MI Phase IIa trial through completion and topline data readout, whilst advancing stroke opportunity towards Phase IIa study and oncology towards Phase Ib study rsonal use only USE OF FUNDS A$M SOURCE OF FUNDS A$M Clinical development
Slide 26: Indicative Timetable
Indicative Timetable Key dates for the Offer below Indicative capital raising timetable1 Date (AEST2) rsonal use only Trading Halt & Placement Bookbuild Opens Thursday, 17 September 2026 SPP record date 7:00pm Friday, 18 September 2026 Capital Raising announced & Trading Halt lifted Monday, 21 Septe
Slide 27: Appendices
rsonal use only Appendices
Slide 28: Corporate Overview & Financial Snapshot
Corporate Overview & Financial Snapshot Key Details CDI Price Chart – Last 24 months Stock Code ASX:NYR rsonal use only $1.40 CDI Price (16 September 2026) A$0.73 Number of CDIs on Issue ~247.6m $1.20 Market Capitalisation (16 September 2026) ~A$180.7m $1.00 Cash Balance (30 June 2026) A$8.4m Number
Slide 29: Key Links
Key Links • Cardioprotection • PROTECT-MI website - https://www.protect-mi.com rsonal use only • PROTECT-MI NIH Entry - https://bit.ly/4cB2fF9 • Phase IIa factsheet - https://bit.ly/4bcDlKj • Preclinical cardioprotection study 1a - https://bit.ly/4sigwMZ • Preclinical cardioprotection study 1b - htt
Slide 30: International Offer Restrictions
International Offer Restrictions This document does not constitute an offer of New CDIs in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New CDIs may not be offered or sold, in any country outside Australia except to the ex
Slide 31: International Offer Restrictions
International Offer Restrictions Singapore This document and any other materials relating to the New CDIs have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other document or materials in conn
Slide 32: International Offer Restrictions
International Offer Restrictions Restrictions under Regulation S under the US Securities Act NYR’s CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act and in accordance with the procedures established pursuant to the provisions of a no-action
Slide 33: International Offer Restrictions
International Offer Restrictions Requirements of any lead manager and ASX Participating Organisations The no-action letter requires that any lead manager and ASX Participating Organisations (brokers that are members of ASX) take certain actions in order to comply with the provisions of the no-action